Oric Historical Financial Ratios

ORIC Stock

USD 9.80 0.07 0.71%

Oric Pharmaceuticals is promptly reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Oric Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

About Oric Financial Ratios Analysis

Oric PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Oric Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Oric financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Oric Pharmaceuticals history.

Oric Pharmaceuticals Financial Ratios Chart

At present, Oric Pharmaceuticals' Income Quality is projected to slightly decrease based on the last few years of reporting. The current year's Current Ratio is expected to grow to 18.35, whereas PTB Ratio is forecasted to decline to 2.01.

Days Sales Outstanding Payables Turnover Cash Per Share Days Payables Outstanding Net Current Asset Value Company Equity Multiplier

Add Fundamental

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Oric Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Oric Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oric Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.At present, Oric Pharmaceuticals' Income Quality is projected to slightly decrease based on the last few years of reporting. The current year's Current Ratio is expected to grow to 18.35, whereas PTB Ratio is forecasted to decline to 2.01.

	2021	2022	2023	2024 (projected)
Current Ratio	15.87	13.68	10.39	18.35
Net Debt To EBITDA	2.87	0.7	0.12	0.11

Current Ratio Net Debt To E B I T D A

Oric Pharmaceuticals fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A	Current Ratio
Ptb Ratio		-0.43	0.61	0.81	-0.51	1.0	0.82	-0.91	0.66	-0.27	-0.65	-0.85	-0.38	-0.33	-0.85	0.11	0.54	-0.92	-0.87	-0.85	-0.91	-0.87	0.65	0.47	-0.1	-0.62
Book Value Per Share	-0.43		-0.4	-0.77	0.4	-0.43	-0.77	0.18	-0.9	-0.04	0.92	0.58	0.14	0.46	0.58	0.25	-0.96	0.17	0.6	0.68	0.63	0.6	-0.52	-0.18	-0.07	0.74
Free Cash Flow Yield	0.61	-0.4		0.77	-0.88	0.61	0.77	-0.3	0.49	0.13	-0.37	-0.87	-0.46	-0.3	-0.87	-0.26	0.3	-0.32	-0.85	-0.83	-0.56	-0.85	0.99	0.7	0.42	-0.14
Operating Cash Flow Per Share	0.81	-0.77	0.77		-0.62	0.81	1.0	-0.54	0.91	0.09	-0.85	-0.94	-0.44	-0.6	-0.94	-0.17	0.76	-0.55	-0.94	-0.98	-0.79	-0.94	0.84	0.59	0.28	-0.68
Capex To Depreciation	-0.51	0.4	-0.88	-0.62		-0.51	-0.63	0.31	-0.41	-0.07	0.36	0.69	0.05	-0.08	0.69	0.35	-0.35	0.31	0.69	0.66	0.54	0.69	-0.88	-0.3	-0.09	0.13
Pb Ratio	1.0	-0.43	0.61	0.81	-0.51		0.82	-0.91	0.66	-0.27	-0.65	-0.85	-0.38	-0.33	-0.85	0.11	0.54	-0.92	-0.87	-0.85	-0.91	-0.87	0.65	0.47	-0.1	-0.62
Free Cash Flow Per Share	0.82	-0.77	0.77	1.0	-0.63	0.82		-0.55	0.91	0.09	-0.85	-0.94	-0.43	-0.59	-0.94	-0.17	0.76	-0.55	-0.94	-0.98	-0.79	-0.94	0.85	0.58	0.28	-0.68
Roic	-0.91	0.18	-0.3	-0.54	0.31	-0.91	-0.55		-0.45	0.36	0.49	0.57	0.11	0.06	0.57	-0.23	-0.37	1.0	0.61	0.58	0.78	0.61	-0.33	-0.15	0.37	0.57
Net Income Per Share	0.66	-0.9	0.49	0.91	-0.41	0.66	0.91	-0.45		0.09	-0.98	-0.72	-0.23	-0.55	-0.72	-0.09	0.91	-0.45	-0.73	-0.81	-0.69	-0.72	0.61	0.31	0.21	-0.87
Payables Turnover	-0.27	-0.04	0.13	0.09	-0.07	-0.27	0.09	0.36	0.09		0.02	-0.07	-0.01	-0.4	-0.06	-0.72	0.0	0.37	-0.03	-0.06	0.43	-0.02	0.14	-0.01	0.53	0.24
Cash Per Share	-0.65	0.92	-0.37	-0.85	0.36	-0.65	-0.85	0.49	-0.98	0.02		0.65	0.12	0.45	0.65	0.07	-0.96	0.48	0.67	0.75	0.73	0.66	-0.5	-0.17	-0.01	0.91
Pocfratio	-0.85	0.58	-0.87	-0.94	0.69	-0.85	-0.94	0.57	-0.72	-0.07	0.65		0.57	0.58	1.0	0.24	-0.57	0.59	1.0	0.99	0.8	1.0	-0.9	-0.71	-0.26	0.45
Interest Coverage	-0.38	0.14	-0.46	-0.44	0.05	-0.38	-0.43	0.11	-0.23	-0.01	0.12	0.57		0.72	0.57	-0.12	-0.07	0.14	0.54	0.53	0.29	0.53	-0.44	-0.88	-0.55	-0.03
Capex To Operating Cash Flow	-0.33	0.46	-0.3	-0.6	-0.08	-0.33	-0.59	0.06	-0.55	-0.4	0.45	0.58	0.72		0.58	0.27	-0.41	0.08	0.56	0.6	0.26	0.55	-0.35	-0.66	-0.53	0.3
Pfcf Ratio	-0.85	0.58	-0.87	-0.94	0.69	-0.85	-0.94	0.57	-0.72	-0.06	0.65	1.0	0.57	0.58		0.23	-0.57	0.59	1.0	0.99	0.8	1.0	-0.9	-0.71	-0.25	0.45
Days Payables Outstanding	0.11	0.25	-0.26	-0.17	0.35	0.11	-0.17	-0.23	-0.09	-0.72	0.07	0.24	-0.12	0.27	0.23		-0.2	-0.25	0.24	0.22	-0.04	0.24	-0.27	0.08	-0.03	-0.22
Income Quality	0.54	-0.96	0.3	0.76	-0.35	0.54	0.76	-0.37	0.91	0.0	-0.96	-0.57	-0.07	-0.41	-0.57	-0.2		-0.36	-0.6	-0.67	-0.7	-0.6	0.44	0.06	-0.09	-0.81
Roe	-0.92	0.17	-0.32	-0.55	0.31	-0.92	-0.55	1.0	-0.45	0.37	0.48	0.59	0.14	0.08	0.59	-0.25	-0.36		0.62	0.59	0.79	0.62	-0.34	-0.18	0.35	0.56
Ev To Operating Cash Flow	-0.87	0.6	-0.85	-0.94	0.69	-0.87	-0.94	0.61	-0.73	-0.03	0.67	1.0	0.54	0.56	1.0	0.24	-0.6	0.62		0.99	0.84	1.0	-0.88	-0.68	-0.18	0.47
Pe Ratio	-0.85	0.68	-0.83	-0.98	0.66	-0.85	-0.98	0.58	-0.81	-0.06	0.75	0.99	0.53	0.6	0.99	0.22	-0.67	0.59	0.99		0.82	0.99	-0.88	-0.67	-0.24	0.55
Return On Tangible Assets	-0.91	0.63	-0.56	-0.79	0.54	-0.91	-0.79	0.78	-0.69	0.43	0.73	0.8	0.29	0.26	0.8	-0.04	-0.7	0.79	0.84	0.82		0.84	-0.61	-0.37	0.29	0.66
Ev To Free Cash Flow	-0.87	0.6	-0.85	-0.94	0.69	-0.87	-0.94	0.61	-0.72	-0.02	0.66	1.0	0.53	0.55	1.0	0.24	-0.6	0.62	1.0	0.99	0.84		-0.88	-0.67	-0.18	0.47
Earnings Yield	0.65	-0.52	0.99	0.84	-0.88	0.65	0.85	-0.33	0.61	0.14	-0.5	-0.9	-0.44	-0.35	-0.9	-0.27	0.44	-0.34	-0.88	-0.88	-0.61	-0.88		0.67	0.41	-0.27
Intangibles To Total Assets	0.47	-0.18	0.7	0.59	-0.3	0.47	0.58	-0.15	0.31	-0.01	-0.17	-0.71	-0.88	-0.66	-0.71	0.08	0.06	-0.18	-0.68	-0.67	-0.37	-0.67	0.67		0.63	-0.06
Net Debt To E B I T D A	-0.1	-0.07	0.42	0.28	-0.09	-0.1	0.28	0.37	0.21	0.53	-0.01	-0.26	-0.55	-0.53	-0.25	-0.03	-0.09	0.35	-0.18	-0.24	0.29	-0.18	0.41	0.63		0.11
Current Ratio	-0.62	0.74	-0.14	-0.68	0.13	-0.62	-0.68	0.57	-0.87	0.24	0.91	0.45	-0.03	0.3	0.45	-0.22	-0.81	0.56	0.47	0.55	0.66	0.47	-0.27	-0.06	0.11

Click cells to compare fundamentals

Oric Pharmaceuticals Account Relationship Matchups

Oric Pharmaceuticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	8.76	2.56	2.04	1.05	2.11	2.01
Book Value Per Share	2.94	13.21	7.19	5.61	4.36	3.52
Free Cash Flow Yield	(0.0315)	(0.0618)	(0.11)	(0.33)	(0.18)	(0.19)
Operating Cash Flow Per Share	(0.79)	(2.06)	(1.57)	(1.89)	(1.67)	(1.75)
Capex To Depreciation	0.58	0.75	0.69	1.05	2.15	0.82
Pb Ratio	8.76	2.56	2.04	1.05	2.11	2.01
Free Cash Flow Per Share	(0.81)	(2.09)	(1.59)	(1.95)	(1.68)	(1.77)
Roic	(0.31)	(0.34)	(0.29)	(0.42)	(0.49)	(0.52)
Net Income Per Share	(0.85)	(4.43)	(2.05)	(2.31)	(1.96)	(2.06)
Payables Turnover	6.58	1.28	0.48	0.73	1.09	2.07
Cash Per Share	2.98	13.38	6.24	5.2	4.05	3.99
Pocfratio	(32.75)	(16.41)	(9.37)	(3.11)	(5.52)	(5.8)
Capex To Operating Cash Flow	(0.0326)	(0.0147)	(0.0158)	(0.0277)	(0.009908)	(0.0104)
Pfcf Ratio	(31.71)	(16.17)	(9.22)	(3.02)	(5.47)	(5.74)
Days Payables Outstanding	55.48	284.85	767.44	498.76	333.88	286.0
Income Quality	0.88	0.61	0.76	0.84	0.85	0.92
Roe	(0.29)	(0.34)	(0.28)	(0.41)	(0.45)	(0.47)
Ev To Operating Cash Flow	(28.96)	(14.67)	(5.61)	(2.25)	(5.37)	(5.64)
Pe Ratio	(30.24)	(7.64)	(7.18)	(2.55)	(4.7)	(4.94)
Return On Tangible Assets	(0.27)	(0.33)	(0.26)	(0.37)	(0.4)	(0.42)
Ev To Free Cash Flow	(28.04)	(14.46)	(5.52)	(2.19)	(5.32)	(5.58)
Earnings Yield	(0.0331)	(0.13)	(0.14)	(0.39)	(0.21)	(0.22)
Net Debt To E B I T D A	3.24	1.06	2.87	0.7	0.12	0.11
Current Ratio	16.81	32.96	15.87	13.68	10.39	18.35
Tangible Book Value Per Share	2.94	13.21	7.28	5.69	4.36	3.54
Graham Number	7.51	36.29	18.2	17.06	13.85	12.1
Shareholders Equity Per Share	2.94	13.21	7.19	5.61	4.36	3.52
Capex Per Share	0.0257	0.0304	0.0247	0.0524	0.0165	0.0221
Graham Net Net	2.78	12.96	5.57	4.58	3.5	3.03
Enterprise Value Over E B I T D A	(24.74)	(8.95)	(4.28)	(1.85)	(4.19)	(4.4)
Price Earnings Ratio	(30.24)	(7.64)	(7.18)	(2.55)	(4.7)	(4.94)
Price Book Value Ratio	8.76	2.56	2.04	1.05	2.11	2.01
Price Earnings To Growth Ratio	1.25	(0.0181)	0.13	(0.2)	0.31	0.19
Days Of Payables Outstanding	55.48	284.85	767.44	498.76	333.88	286.0
Price To Operating Cash Flows Ratio	(32.75)	(16.41)	(9.37)	(3.11)	(5.52)	(5.8)
Price To Free Cash Flows Ratio	(31.71)	(16.17)	(9.22)	(3.02)	(5.47)	(5.74)
Ebt Per Ebit	0.94	0.99	1.0	0.97	0.91	1.06
Effective Tax Rate	0.052	(0.32)	0.0132	(0.0264)	(0.0304)	(0.0319)
Company Equity Multiplier	1.07	1.03	1.09	1.11	1.12	0.67
Return On Capital Employed	(0.32)	(0.26)	(0.28)	(0.4)	(0.48)	(0.5)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:

How To Invest In Oric

Details

Is Oric Stock a good investment?

Details

What is Oric Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oric Pharmaceuticals. If investors know Oric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oric Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.87)

Return On Assets

(0.29)

Return On Equity

(0.46)

The market value of Oric Pharmaceuticals is measured differently than its book value, which is the value of Oric that is recorded on the company's balance sheet. Investors also form their own opinion of Oric Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Oric Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oric Pharmaceuticals' market value can be influenced by many factors that don't directly affect Oric Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Oric Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oric Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Oric Historical Financial Ratios

About Oric Financial Ratios Analysis

Oric Pharmaceuticals Financial Ratios Chart

Payables Turnover

Oric Pharmaceuticals fundamentals Correlations

Oric Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oric Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Roe	+ 1.0	Roic
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Pocfratio

Cash Per Share	- 0.98	Net Income Per Share
Pe Ratio	- 0.98	Free Cash Flow Per Share
Pe Ratio	- 0.98	Operating Cash Flow Per Share
Income Quality	- 0.96	Cash Per Share
Income Quality	- 0.96	Book Value Per Share
Ev To Free Cash Flow	- 0.94	Free Cash Flow Per Share